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ABSTRACT: Proteinaceous aggregation is a well-known
observable in Alzheimer’s disease (AD), but failure and storage
of lysosomal bodies within neurons is equally ubiquitous and
actually precedes bulk accumulation of extracellular amyloid
plaque. In fact, AD shares many similarities with certain
lysosomal storage disorders though establishing a biochemical
connection has proven diﬃcult. Herein, we demonstrate that
isomerization and epimerization, which are spontaneous
chemical modiﬁcations that occur in long-lived proteins,
prevent digestion by the proteases in the lysosome (namely,
the cathepsins). For example, isomerization of aspartic acid into
L-isoAsp prevents digestion of the N-terminal portion of Aβ by
cathepsin L, one of the most aggressive lysosomal proteases.
Similar results were obtained after examination of various target peptides with a full series of cathepsins, including endo-,
amino-, and carboxy-peptidases. In all cases peptide fragments too long for transporter recognition or release from the lysosome
persisted after treatment, providing a mechanism for eventual lysosomal storage and bridging the gap between AD and
lysosomal storage disorders. Additional experiments with microglial cells conﬁrmed that isomerization disrupts proteolysis in
active lysosomes. These results are easily rationalized in terms of protease active sites, which are engineered to precisely orient
the peptide backbone and cannot accommodate the backbone shift caused by isoaspartic acid or side chain dislocation resulting
from epimerization. Although Aβ is known to be isomerized and epimerized in plaques present in AD brains, we further
establish that the rates of modiﬁcation for aspartic acid in positions 1 and 7 are fast and could accrue prior to plaque formation.
Spontaneous chemistry can therefore provide modiﬁed substrates capable of inducing gradual lysosomal failure, which may play
an important role in the cascade of events leading to the disrupted proteostasis, amyloid formation, and tauopathies associated
with AD.
■ INTRODUCTION
The active balancing of protein synthesis and degradation, or
proteostasis, is an ongoing and critical process in most cells.1
Proteins must be created, carry out their requisite function, and
then be recycled once they are no longer needed or have
become nonfunctional. Several pathways are available for
protein degradation, including the proteasome, macroautoph-
agy, microautophagy, and chaperone-mediated autophagy.2,3
The autophagy-related pathways deliver proteins to lysosomes,
which are acidic organelles containing a host of hydrolases,
including many proteases.4 Cargo taken into cells via
endocytosis is also typically delivered to lysosomes for
degradation. Regardless of the pathway, after cargo fuses
with a lysosome, endopeptidases cleave proteins at internal
sites, shortening proteins to peptides, which are then further
digested from both termini by exopeptidases. After protein
digestion has been completed, transporter proteins in the
lysosomal membrane release (primarily) individual amino
acids back into the cytosol for new protein synthesis or energy
production.5 Lysosomes are crucial for maintaining cellular
homeostasis, but they are also uniquely susceptible to
problems when substrates cannot be hydrolyzed. For example,
genetic modiﬁcations reducing the eﬃcacy of a lysosomal
hydrolase are the most common cause of lysosomal storage
disorders. These devastating diseases involve “storage” of failed
lysosomal bodies within cells, which eventually leads to cell
death and is particularly problematic for postmitotic cells such
as neurons.6 Symptoms in lysosomal storage disorders usually
emerge in infancy or childhood, are often associated with
neurodegeneration, and are typically fatal.7
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Long-lived proteins8 are a primary target of the lysosome
because they become modiﬁed and lose eﬃcacy over time. A
well-known example of this occurs with mitophagy,3 wherein
old mitochondria are recycled in their entirety. Contributing
factors that lead to long-lived protein deterioration include a
variety of spontaneous chemical modiﬁcations, i.e., modiﬁca-
tions not under enzymatic control.8 Some of these
modiﬁcations are very subtle and diﬃcult to detect, including
isomerization and epimerization.9 Isomerization occurs
primarily at aspartic acid, when the side chain inserts into
and elongates the peptide backbone (Scheme 1).10 Identical
products are also created during deamidation of asparagine,
which further results in chemical transformation from one
amino acid to another.11 Epimerization occurs when an amino
acid side chain inverts chirality from the L- to D- conﬁguration.
Peptide isomerization and epimerization do not have readily
identiﬁable bioanalytical signatures, but both modulate
structure in a subtle, yet signiﬁcant, way (see Figure 1).
Studies on the eye lens have shown that epimerization and
isomerization are among the most abundant modiﬁcations
observed in extremely long-lived proteins.12−14 However,
knockout experiments in mice have also revealed the
importance of these modiﬁcations over much shorter time
scales. For example, removal of the repair enzyme for L-isoAsp,
protein-isoaspartyl methyl transferase (PIMT),15 leads to lethal
accumulation of isomerized protein in just 4−6 weeks.16,17
This reveals that isomerization of aspartic acid is suﬃciently
dangerous that an enzyme has evolved to repair it.
The importance of peptide isomers is further revealed in the
uses nature has found for them. For example, single amino acid
sites are intentionally epimerized in many venoms and in
signaling neuropeptides in crustaceans.18,19 The corresponding
L-only peptides are not biologically active, conﬁrming the
importance of the chiral modiﬁcations. In addition, it is
thought that epimerization is beneﬁcial for these peptides
because it allows them to escape, or prolong the time required
for, proteolysis.20 In fact, it is well-known that sites of
epimerization and isomerization are both generally resistant to
protease action, but the ramiﬁcations of such chemistry in the
context of lysosome function have not been previously
examined. Despite this absence, numerous studies have
established the importance of protein degradation in
lysosomes. For example, knockout mice lacking cathepsin D
grow normally for ∼2 weeks but then die before the end of 4
weeks.21 Examination of the neurons from these mice revealed
an abundance of failed lysosomal bodies, similar to those
observed in lysosomal storage disorders. Other research has
shown that knockout mice lacking cathepsins B and L die
within 2−4 weeks of birth. Again, accumulation of failed
lysosomal bodies was observed in neurons of these mice.22
Although cathepsins can also be found outside the lysosome,23
these results conﬁrm a signiﬁcant, and likely fatal, impact on
the lysosomal system when critical cathepsins are absent.
Amyloid aggregates or proteins that are otherwise insoluble
are also targeted to lysosomes for degradation.24 Amyloid
aggregation has also captured the majority of attention as the
potential cause of Alzheimer’s disease (AD), but signiﬁcant
evidence also supports lysosomal storage as an underlying
cause. For example, AD shares many pathological similarities
with lysosomal storage disorders, including proliﬁc storage of
failed lysosomal bodies, accumulation of senile plaques, and
formation of neuroﬁbrillary tangles.25,26 In fact, scanning-
electron microscopy images of lysosomal storage (in neurons)
are virtually indistinguishable between the two diseases. The
lysosomal storage observed in AD precedes formation of
amyloid deposits,27 hinting that lysosomal malfunction may
occur upstream of the events leading to extracellular amyloid
aggregation. The parallels between the two diseases have also
been oﬀset by diﬀerences. For example, lysosomal storage
disorders typically aﬄict youth and can progress rapidly, while
AD typically occurs late in life over a longer time scale.
Therefore, a mechanism accounting for the commonalities and
diﬀerences between the diseases has been diﬃcult to identify,
but an intriguing possibility does exist.
The primary constituents of senile plaques, Aβ and Tau, are
both long-lived proteins that are subject to isomerization and
epimerization.8 In fact, Aβ is signiﬁcantly epimerized and
isomerized in the brains of people with AD.28 If isomerization
and epimerization prevent lysosomal protein digestion, then a
common link between lysosomal storage disorders and AD
would be established. In fact, AD would essentially represent a
diﬀerent type of lysosomal storage disorder, one that operates
in reverse of the classical disease. Rather than failure of a
modif ied enzyme or modif ied transporter to clear waste
Scheme 1. Pathways for Isomerization of Aspartic Acid and Deamidation of Asparagine
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molecules, failure to digest or transport modif ied waste
molecules would be operative and eventually lead to lysosomal
storage. Close examination of another complex age-related
disease, macular degeneration, reveals that there is precedence
for substrate-induced lysosomal storage.29
Herein, we use mass spectrometry (MS) and liquid
chromatography (LC) to demonstrate that isomerized or
epimerized peptides resist degradation by cathepsins, including
both endo- and exopeptidase activity. Important target
peptides that are both long-lived and closely associated with
AD were examined, including fragments of Aβ and Tau. The
results reveal that small peptide fragments composed of
residues surrounding isomerized or epimerized sites persist
after digestion. Disrupted proteolysis was observed in both
isolated reactions on model peptides in full-length Aβ, and in
living cells, oﬀering an explanation for the toxicity observed in
previous experiments with cell and animal models employing
isomerized Aβ (see the discussion below). Additional experi-
ments reveal that the rates of isomerization for the Asp
residues in the N-terminal portion of Aβ are fast, providing a
pathway for generation of these toxic species that could
eventually lead to lysosomal failure and initiate other
downstream consequences.
■ RESULTS AND DISCUSSION
Deﬁning Limitations of Cathepsin Digestion. A series
of isolated digestions of synthetic peptides both in canonical
form and with isomerized or epimerized (iso/epi) sites were
performed, and the results are summarized in Figure 2.
Experiments were conducted with cathepsins D, L, B, and H.
This collection includes all of the most abundant cathepsins
and all modes of function, i.e., endo-, carboxy-, and
aminopeptidases.30,31 The peptide APSWFDTGLSEMR
(αB57−69), derived from αB-crystallin, was used as the initial
test substrate. It contains both Ser and Asp residues known to
be modiﬁed in the eye lens.32 Furthermore, Ser59, Asp62, and
Ser66 are each separated by other residues, allowing for semi-
independent examination. Furthermore, the canonical se-
quence is a good substrate for proteolysis. Digestion of the
native form with cathepsin D in acetate buﬀer at pH 4.5 yields
the results shown in the upper part of Figure 2a. The LC-MS
derived ion chromatogram reveals many peptide fragments and
almost complete consumption of the precursor. Clearly, the
canonical all-L version of APSWFDTGLSEMR is easily
digested. Substitution of L-Asp with L-isoAsp yields the lower
chromatogram, where after 6 h, the precursor remains basically
untouched. A single modiﬁcation therefore prevents cathepsin
D from digesting an entire 13 residue sequence, shutting down
peptide hydrolysis at seven diﬀerent sites. To more easily
visualize the results in a condensed fashion, peptide fragments
resulting from proteolysis are represented by color-coded lines
below the peptide sequence as shown in Figure 2b (full
chromatograms are also provided in the Supporting
Information). The data from Figure 2a correspond to the
top two rows of the results shown in Figure 2b. Data for the
other Asp isomers and both Ser epimers are shown in the
remaining slots of Figure 2b. All three non-native forms of
aspartic acid essentially prevent digestion by cathepsin D.
Furthermore, epimerization of the less bulky serine side chain
also modulates cathepsin D action, preventing cleavage at one
or more preferred sites even when the epimerized serine is
located six residues away. Signiﬁcant residual precursor is
detected for all modiﬁcations, suggesting decreased aﬃnity for
the iso/epi modiﬁed peptides in general. Results for analogous
experiments conducted in acetate buﬀer at pH 5.5 with
cathepsin L are shown in Figure 2c. The canonical peptide is
digested into many peptide fragments, including small di- and
tripeptides. Cathepsin L is one of the most aggressive
lysosomal proteases and is able to cleave more sites in the
iso/epi modiﬁed peptides relative to cathepsin D. Further-
more, precursor survival is not observed with cathepsin L.
However, the sites where digestion occurs are all shifted well
away from iso/epi modiﬁed residues in every instance, and the
number of peptide fragments observed is still reduced relative
to the canonical form. The results from cathepsin L and D
reveal that digestion by endopeptidase action is signiﬁcantly
hampered by iso/epi modiﬁcations across wide regions of
sequence.
The lysosomal task of reducing proteins and peptides into
individual amino acids is never completed by endopeptidases,
making examination of exopeptidases important. We used a
palindromic peptide (RLHTIDITHLR) to systematically
explore the limits of exopeptidase activity, and the results for
experiments with cathepsins H and B are shown in Figure 2d.
For cathepsin B, the canonical sequence is rapidly degraded
(CatB upper trace). None of the precursor remains, and only a
few fragments are detectable. This is consistent with thorough
digestion, producing amino acids or peptides too small to be
retained on the column. In contrast, placement of an
isomerized residue in the central position, D-isoAsp, halts
digestion considerably (CatB lower trace). The most abundant
product corresponds to a single cleavage, removal of the C-
terminal LR dipeptide. When acting as an exopeptidase,
cathepsin B preferentially removes dipeptides.30 Note,
endopeptidase activity leads to the bond cleavages observed
on the N-terminal side of the peptide. Similar results are
obtained for cathepsin H, which behaves as an aminopeptidase,
removing a single N-terminal amino acid at a time.30 The
native peptide precursor is completely depleted (CatH upper
trace), but a few larger peptide fragments remain relative to
digestion by cathepsin B. This may relate to reduced aﬃnity or
slower progress due to removal of a single amino acid at a time.
In any case, the isomerized peptide is digested noticeably less
under identical conditions (CatH lower trace). Interestingly,
cathepsin H is able to penetrate within one amino acid of the
iso/epi residue compared with two for cathepsin B. This can
be rationalized because cathepsin H does not need to
accommodate two amino acids in the catalytic site. Some
endopeptidase activity is also observed for cathepsin H. Similar
results were obtained in experiments examining L-Ser versus D-
Ser in the central position (see Figure S14). Taken together,
these results illustrate signiﬁcant disruption of proteolysis by
Figure 1. Model structures of the aspartic acid isomers, where the
isostructure conformation closest to native backbone orientation is
shown. Two views are illustrated for each isomer.
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iso/epi modiﬁcations for both the major endo- and
exopeptidases in the lysosome.
The results for additional peptide targets relevant to AD are
shown in Figure 2e,f (Aβ1−9 and Tau 594IINKKLDL601). The
two aspartic acids near the N-terminus of Aβ, Asp1, and Asp7
are highly isomerized in amyloid plaques28 and represent an
interesting target where multiple proximal iso/epi modiﬁca-
tions can be found. Isomerization of Aβ is known to inhibit
serum protease action, suggesting that cathepsins may likewise
be stymied.33 Experiments conducted on canonical Aβ1−9 and
a double isomer (L-isoAsp1, D-isoAsp7) are summarized in
Figure 2e, where the fraction of remaining precursor from each
peptide is shown for each cathepsin. Cathepsin B and L easily
deplete the precursor for the canonical peptide but are unable
to signiﬁcantly reduce the amount of precursor for the double
isomer. Interestingly, cathepsin D cleaves few sites34 in Aβ and
is unable to cleave any portion of Aβ1−9 even in canonical
form. Similarly, cathepsin H exhibits low aﬃnity for the N-
terminal residues in Aβ1−9 and digests the canonical peptide
only marginally while leaving the isomerized form intact. The
N-terminal portion of Aβ is therefore generally resistant to
lysosomal protease action and home to multiple sites of
modiﬁcation that can further frustrate proteolysis, making the
prospects for Aβ to contribute to lysosomal failure strong.
Experiments on an aged sample of Aβ1−42 yielded similar
results (Figure S13). The highly isomerized N-terminal region
was not digested by Cathepsin L while digestion of the C-
terminal portion not proximal to any isomerization was cleaved
in comparable fashion for both native and aged Aβ1−42.
Tau-mediated pathology is also strongly associated with AD,
making it an important target to consider.35 Asn596 in Tau is
known to deamidate,36 which will yield conversion to Asp and
iso/epi modiﬁcations according to the pathway illustrated in
Scheme 1. As a long-lived protein, Tau could also isomerize at
Asp600. Isomerization at both sites is explored for the peptide
fragment 594IINKKLDL601 in Figure 2f for cathepsins B, L, and
H. The canonical peptide is rapidly consumed for all three
cathepsins, but introduction of D-isoAsp at either position
signiﬁcantly perturbs the locations of proteolytic cleavage sites
and leads to observation of abundant undigested precursor in
all cases. These results reveal that inhibited proteolysis in the
vicinity of iso/epi modiﬁed residues is likely a general feature
for any peptide sequence, and long-lived proteins known to be
modiﬁed in the brain will be diﬃcult for the lysosome to break
down into amino acids.
Isomer Digestion in Living Cells. To explore additional
lysosomal proteases, experiments were conducted with fully
active lysosomes in SIM-A9 mouse microglial cells, as shown in
Figure 3. For the peptide target, the N-terminal portion of Aβ
was selected, and microglial cells were used because they are
active participants in the clearance of Aβ within the brain.37
Chimeric peptides (R8-EedanDAEFRHDKdabG, where the Glu
and Lys have been modiﬁed with edans and dabcyl,
respectively) consisting of a cell-penetrating portion combined
with an Aβ probe sequence were synthesized. Polyarginine was
used for cell penetration, which is known to deliver cargo to
the lysosome.38 The probe portion of the peptide remains dark
when intact as the edans ﬂuorescence is eﬃciently quenched
by dabcyl. Upon cleavage of the probe sequence, the quencher
can separate, and edans will emit broadly around 490 nm.
Results for Aβ1−7 (L-Asp1, L-Asp7) as the probe are shown in
Figure 3a, revealing that ﬂuorescence is observed after 150 min
as expected. In comparison, the D-isoAsp1/D-isoAsp7 probe
yields lower intensity ﬂuorescence in terms of quartile range,
median, and number (including exceptionally bright cells), as
shown in Figure 3b. Statistical comparison of the results with
the Mann−Whitney U test reveals that diﬀerences in digestion
are signiﬁcant for all time points. Higher resolution images
conﬁrmed that the ﬂuorescence was punctate and overlapping
with organelles stained by lysotracker, consistent with delivery
to the endosomal/lysosomal system (Figures S8 and S9).
Taken together, these results suggest that there is not an
unknown protease in the lysosome engineered to digest iso/epi
sites.
Interestingly, the microglial results can be largely recapitu-
lated by examination of the same chimeric peptide incubated
with only cathepsin L, as shown in Figure 3c and Figure S1.
Both the rates and magnitude of the diﬀerential closely match
Figure 2. (a) LC chromatogram for digestion of APSWFDTGLSEMR by cathepsin D. Summary of digestion by (b) cathepsin D and (c) cathepsin
L. Each bar represents a fragment detected in the LC-MS chromatogram, color-coded by N-terminal (blue), C-terminal (gold), and internal
(green). Undigested precursor >50% relative intensity is represented by a black line. (d) LC chromatograms for digestion of RLHTIDITHLR by
exopeptidases cathepsins B and H for the native isomer (upper traces) and D-isoAsp isomer (lower traces). (e) Summary of digestion of Aβ1−9 (L-
Asp1, L-Asp7) vs (L-isoAsp1, D-isoAsp7) by major cathepsins. Only the canonical isomer is digested. (f) Summary of digestion of 594IINKKLDL601
from Tau using the same color scheme.
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the results obtained in living cells. These ﬁndings are
consistent with previous observations that cathepsin L is one
of the most important lysosomal proteases and can account for
∼40% of all protein digestion in the lysosome.30 The accurate
reproduction conﬁrms the validity of the LC-MS approach that
yielded the results shown Figure 2. Furthermore, the eﬀects of
iso/epi modiﬁcations are more accurately determined under
controlled incubation where canonical peptides without
additional modiﬁcations can be tested. For example, Aβ1−7
(D-isoAsp, D-isoAsp) itself is almost completely resistant to
degradation, yet proteolysis with cathepsin L is increased by a
factor of ∼7 after decoration with hydrophobic chromophores
needed for examination in cells (Figure S2). This suggests that
the diﬀerence between digestions shown in Figure 3b is
signiﬁcantly underestimated relative to the true inhibiting
power of the D-isoAsp modiﬁcations.
The results in Figures 2 and 3a,b can easily be rationalized
by a molecular level inspection of the interaction between a
protease and substrate peptide. In Figure 3d, the X-ray crystal
structure for binding of a peptide substrate to cathepsin L is
shown.39 The protease active site consists of a channel where
several hydrogen bonds orient the peptide backbone of the
substrate. Intimate contact and alignment of the substrate
backbone is required to bring the cleavage site into proximity
with the catalytic actors. Favorable or unfavorable interactions
with side chains protruding above the groove determine the
sequence selectivity, but introduction of a D-amino acid with
the peptide backbone remaining properly oriented would result
in the side chain projecting directly into the wall of the binding
groove (Figure 3e). Similarly, isoAsp modiﬁcations disrupt
both the backbone hydrogen bond partner spacing and relative
orientation (Figure 1), making for an even less tractable
situation. These structural alterations make it impossible for
iso/epi modiﬁed residues to ﬁt properly into the catalytic
binding site. Given the similarities inherent in the function and
substrate for every protease, comparable complications are
likely to exist for all proteases intended to cleave peptides
composed solely of canonical L-residues. Perhaps it is not
surprising that poor proteolysis is observed for iso/epi
modiﬁed peptides even in glial cells where a full complement
of lysosomal proteases is available.
Time Frame for Aspartic Acid Isomerization. Given
that Aβ plays an important role in Alzheimer’s disease (AD)
and is highly isomerized in amyloid plaques,28,40 we set out to
determine the incubation times needed to yield such extensive
modiﬁcations. Following incubation of Aβ1−40, Aβ1−42, and
Aβ1−9 in tris buﬀer at 37 °C, the degree of isomerization was
measured, and the results are shown as a function of time in
Figure 4a,b. To quantitate the isomerization of Asp1 and Asp7
independently, aged Aβ1−40 and Aβ1−42 were ﬁrst digested
with chymotrypsin, yielding 1DAEF4 and 5RHDSGY10
peptides, which were subsequently analyzed by LC-MS (see
Figures S5 and S6). Isomerization occurs rapidly at both
aspartic acids for both full length peptides, yielding roughly
14% combined isomerization within 30 days. This rate is
comparable to previous examination41 of Aβ1−16 and to
isomerization of Asp151 in αA-crystallin (when determined for
the peptide fragment 146IQTGLDATHAER157).42 It is also
Figure 3. (a) Sample images of SIM-A9 mouse microglial cells after 150 min incubation with cleavable peptide target with all L-residues,
ﬂuorescence from 481 to 499 nm (left), bright-ﬁeld (middle), and overlay (right). (b) Violin plot showing quantitative comparison of ﬂuorescence
intensity per cell from Aβ1−7 cleavage for canonical and the D-isoAsp1/D-isoAsp7 isomers as a function of incubation time. *** p < 0.001. (c)
Fluorescence intensity as a function of time for incubation of same peptide with cathepsin L only. (d) Active site of cathepsin L with native peptide
substrate bound and (e) mutated epimer with D-Asp side chain highlighting inherent steric clash if backbone orientation is maintained. Structures
derived from PDB ID 3K24 with hydrogen bonds indicated by green dashed lines.
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consistent with other isomerization rates cited in the literature
as shown in Figure 4c,10,43−45 where the only signiﬁcantly
faster rates involve Asp−Gly sequences. Detailed study of
deamidation, which forms an identical succinimide ring
intermediate preceding isomerization, revealed the fastest
rates for analogous Asn−Gly sites.46
These experiments were conducted at μM concentrations,
which is suﬃcient for the formation of amyloid ﬁbrils. The
presence of amyloid was examined by ThT assay after 7 days as
shown in Figure 4d. The assay reveals that Aβ1−42 had
already formed ﬁbrils within 7 days, while Aβ1−40 was just
entering ﬁbril formation, consistent with previous reports.47
After digestion with chymotrypsin, the ﬂuorescence diminishes
substantially, suggesting that ﬁbrils are broken up and should
not signiﬁcantly inﬂuence the analysis. Interestingly, amyloid
formation appears to slightly increase the rate of isomerization
for Asp1 but in general does not signiﬁcantly inﬂuence the
rates. This conclusion is further supported by the observation
that the rates do not vary greatly from the results obtained for
Aβ1−9, which does not form ﬁbrils.41
Framework Connecting Lysosomal Failure and AD.
Long-lived proteins are subject to many spontaneous chemical
modiﬁcations, including subtle changes such as iso/epi
modiﬁcations that may seem harmless and are easily
overlooked. Nevertheless, heavy isotope pulse-chase experi-
ments in mice have shown that long-lived proteins in the brain
are more commonplace than previously realized and can
persist for timespans exceeding one year.48 These long-lived
proteins are part of the overall equation that must be balanced
to maintain proteostasis and will therefore be targeted for
degradation at some point. Our results reveal that isomerized
and epimerized sites in long-lived proteins resist digestion by
the primary cathepsins present in lysosomes. Both epimeriza-
tion (Ser and Asp) and isomerization (Asp) eﬀectively prevent
proteolysis at the site of modiﬁcation and nearby residues for
both endo- and exopeptidases. Long-lived proteins targeted to
the lysosome are therefore expected to produce residual
peptide fragments that are too long to be recognized by the
transporters responsible for releasing digested amino acids
back to the cytosol. Additionally, the residual peptides will
contain an unnatural amino acid that would be expected to
further frustrate transporter recognition. Accumulation of these
byproducts within the lysosomal machinery is therefore
possible. In fact, interference with lysosomal function has
already been documented in similar circumstances with
pyroglutamate modiﬁed Aβ, where the inﬂuence on proteolysis
is signiﬁcantly less pronounced.49
We have demonstrated that iso/epi modiﬁcations signiﬁ-
cantly inhibit lysosomal digestion in glial cells, but prior work
has additionally shown that such modiﬁcations are toxic.
Makarov and co-workers have examined isomerization of the
N-terminal portion of Aβ in relation to the idea that such
modiﬁcations enhance amyloid formation in the presence of
zinc ions. They found that isomerized Aβ1−42 was more toxic
than the canonical form when incubated with several diﬀerent
cell lines (NSC-hTERT, SK-N-SH, and SH-SY5Y).50 Fur-
thermore, cell death by apoptosis rather than necrosis was
more prevalent in the case of isomerized Aβ, indicating an
alternate and more speciﬁc mechanistic pathway. Importantly,
related experiments have demonstrated that Aβ localizes into
the lysosome when incubated with SH-SY5Y cells,51 suggesting
that the toxicity could be reasonably attributed to lysosomal
pathology instead. Toxic eﬀects have also been found in animal
studies.52 Perhaps most strikingly, injection of isomerized
Aβ1−16 leads to signiﬁcantly increased amyloid plaque
accumulation in 5XFAD transgenic mice whereas canonical
Aβ1−16 does not.53 Importantly, Aβ1−16 does not contain
the amyloid forming portion of the peptide.54 Although these
data could be interpreted to support to the zinc-mediated
amyloid aggregation hypothesis, our ﬁndings suggest that
disruption of the lysosomal system could also explain the
results. Introduction of isomerized Aβ1−16 could lead to
lysosomal failure, followed by disrupted proteostasis and the
observed increase in amyloid plaque formation.
We have established that isomerization of Aβ is relatively
fast. The residence time of Aβ in the human brain is diﬃcult to
determine due to the multiple destinations and pathways that
can be taken, but studies have shown that the fraction of Aβ
escaping into cerebrospinal ﬂuid persists beyond 30 h in a
healthy individual.55 Similar studies have shown that clearance
Figure 4. Isomerization % as a function of time for (a) Asp1 and (b) Asp7. (c) Average isomerization rate for Asp1 and Asp7 relative to rates from
the literature. (d) ThT assay after 7 days conﬁrming that any ﬁbrils are largely digested during analysis. Data points: 1,43 2,42 3,44 3b,c (estimated
rate of the VYPDGA peptide from the literature point 3 modiﬁed to correspond to VYPDSA and VYPDAA based on known deamidation rates.47),
4,45 and 5.46
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rates for Aβ are mismatched relative to production in AD
individuals,56 which suggests that some fraction evades
degradation and may persist for longer times. The rates in
Figure 4 allow for a small degree of isomerization (∼0.2%)
even within a 30 h time frame. Furthermore, any fraction of Aβ
residing in the brain for a week or more would be expected to
isomerize signiﬁcantly. The N-terminal region of Aβ is
disordered in amyloid structures determined by NMR,55,57
which may allow free access to the required succinimide
intermediate while providing some catalytic interactions that
favor isomerization. Aβ is therefore a likely source of
isomerized residues in the brain, but a few reports have
shown that Tau can also be isomerized due to deamidation at
positions 596 and 698, or isomerization of Asp at positions 510
and 704.58,59 The size and largely unstructured nature of Tau60
make it almost certain that other sites of isomerization also
exist. There is ample evidence that the proteins most strongly
associated with AD pathology are subject to iso/epi
modiﬁcations that could lead to lysosomal failure.
■ CONCLUSION
Iso/epi modiﬁcations are clearly generated on a relatively short
time scale and prevent cathepsin digestion of nearby peptide
bonds. Although other proteolytic pathways exist within cells
that may also encounter diﬃculties with iso/epi modiﬁcations,
lysosomes are uniquely vulnerable because undigested by-
products cannot escape the lysosomal membrane and can
eventually cause failure and storage of the entire organelle.
When this sequence of events is triggered in lysosomal storage
disorders, the consequences are dramatic and often fatal.
Malfunction of the lysosome is also strongly associated with
the pathology of AD, as are misfolding and aggregation of both
Aβ and Tau. Lysosomal failure caused by the iso/epi
modiﬁcations documented to exist in both Aβ and Tau oﬀers
a direct connection between these observations and a potential
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